NCT07543510 2026-04-22
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
Clinical Trials
15 trialsNCT07545954 2026-04-22
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07388524 2026-04-17
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
National Cancer Institute (NCI)
Phase 3 Not yet recruiting
NCT07170592 2026-04-07
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT07322341 2026-03-13
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
Phase 2 Not yet recruiting
NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
NCT07281664 2025-12-15
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
NCT07172412 2025-09-30
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06680258 2025-09-03
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics
Phase 3 Not yet recruiting
NCT06584071 2024-12-16
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Biotheus Inc.
Phase 1/2 Not yet recruiting
NCT06719336 2024-12-05
Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
Peking University Cancer Hospital & Institute
Phase 3 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06572722 2024-08-27
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Phase 2 Not yet recruiting
NCT05859217 2024-05-08
Cabatezo-1
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT05703997 2023-01-30
FASTIMMUNE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting